Secretome Therapeutics
PrivateLast Round
Series A
May 27, 2026
Total Funding Raised
$31.75M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Secretome Therapeutics operates in Healthcare & Life Sciences and is based in Baltimore, Maryland. Its latest recorded funding round was a Series A round in May 2026.
Secretome Therapeutics is a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells to address cardiovascular diseases and inflammatory conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Secretome Therapeutics Comparables
Compare Secretome Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Immunis, Inc. | 84% | |
| Remedy Cell Ltd. | 83% | |
| Micregen | 81% |
For institutional investors. Book with your work email.
Secretome Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 27, 2026 | ||||
| Grant | Mar 24, 2026 | ||||
| VC Round | Nov 25, 2024 | ||||
| Seed | Oct 17, 2019 |
For institutional investors. Book with your work email.
Secretome Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| HEST Investments | VC Round |
| RA Capital Management | Series A |
| Parent Project Muscular Dystrophy | Grant |
| Abell Foundation | Seed |
| TEDCO | Seed |
| UM Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 12, 2026
Open roles increased to 10, 2.5x the trailing average.
- Sep 3, 2026
Grew 41% QoQ from 17 to 24 employees.
For institutional investors. Book with your work email.
Secretome Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Secretome Therapeutics's valuation, stock price, and market status.
Is Secretome Therapeutics a public or private company?
Secretome Therapeutics is a private company.
What is the current stock price of Secretome Therapeutics?
Secretome Therapeutics is a private company, so its shares have no public market price. Caplight tracks Secretome Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Secretome Therapeutics worth (valuation)?
Valuation information for Secretome Therapeutics is not publicly available.
Can I buy Secretome Therapeutics stock?
Secretome Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Secretome Therapeutics's last funding round?
Secretome Therapeutics's most recent funding round was Series A on May 27, 2026.
Who are the main investors in Secretome Therapeutics?
Key investors in Secretome Therapeutics include HEST Investments, RA Capital Management, Abell Foundation.
Will Secretome Therapeutics IPO soon?
No public IPO plans have been announced for Secretome Therapeutics.
How can I track Secretome Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Secretome Therapeutics's shares on secondary markets.